# Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

> **NCT04610684** · PHASE2 · TERMINATED · sponsor: **Jeffrey Clarke** · enrollment: 3 (actual)

## Conditions studied

- Small-cell Lung Cancer
- Brain Metastases

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04610684
- **Lead sponsor:** Jeffrey Clarke
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-05
- **Primary completion:** 2022-07-15
- **Final completion:** 2022-09-20
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Lack of Enrollment
- **Last updated:** 2024-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04610684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04610684, "Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04610684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*